On Friday, in the course of current trade, Shares of Regions Financial Corporation (NYSE:RF), is flat, and is now trading at $10.56.
Regions Bank declared that Nicole Elmore, branch manager in Denham Springs, Louisiana, is the June 2015 recipient of the Regions Bank Better Life Award. The Better Life Award is the top honor given to a Regions associate for outstanding dedication and job performance, as well as exemplary involvement and commitment to the community.
In addition to the recognition, Regions donates $1,000 in the name of the recipient to a nonprofit organization of the winner’s choice. Elmore chose the Pilot Club of Denham Springs. She is assisting the group raise funds to build a baseball field for the local Challenger recreation division, which provides opportunities for special needs children to take part in sports. A video of Elmore is accessible on the Regions Financial YouTube channel.
Elmore is a member of the current Leadership Livingston class through her local chamber of commerce. Her classmates are working with her to fund-raise for the Challenger field. They hope to reach their aim soon.
“It will be a joy to see those children who have had so many obstacles be able to fully take part in a game on a field made just for them,” Elmore said.
Regions Financial Corporation, together with its auxiliaries, provides banking and bank-related services to individual and corporate customers in the United States. Its Corporate Bank segment offers commercial banking services, such as commercial and industrial, commercial real estate, and investor real estate lending, in addition to equipment lease financing services.
During an early morning trade, Shares of Radian Group Inc. (NYSE:RDN), dipped -0.38%, and is now trading at $18.28.
Clayton Holdings LLC, a partner of Radian Group Inc. (NYSE: RDN), provides risk-based analytics, residential loan due diligence, consulting, surveillance and staffing solutions.
Clayton Holdings LLC, declared that Suzanne Singer has joined the company as senior managing director of business development.
In this position, Singer will be responsible for expanding Clayton’s customer base and developing and executing planned initiatives with Clayton’s parent company, Radian Group Inc. She will report directly to Tom Donatacci, Clayton’s executive vice president of sales and marketing.
Singer has had more than 20 years of experience in the mortgage industry. Most recently, she served as executive vice president of sales and marketing for Litigation Guard, a provider of mortgage-lending risk administration tools and technology services. Singer has held various client administration and business development roles at Auction.com, Wingspan Portfolio Advisors, GMAC-RFC and Option One Mortgage Corporation. She began her career as a specialist in the community development investment group at Freddie Mac.
Radian Group Inc., through its auxiliaries, provides mortgage and real estate products and services in the United States. It operates through two segments, Mortgage Insurance, and Mortgage and Real Estate Services (MRES).
Finally, PlasmaTech Biopharmaceuticals, Inc. (NASDAQ:PTBI), lost -0.13% Friday.
PlasmaTech Biopharmaceuticals, declared that it has added another adeno-associated virus (AAV) gene therapy program to its product pipeline. The company has licensed an AAV gene therapy for the treatment of juvenile Batten disease (JBD) from UNeMed Corporation, the technology transfer and commercialization office for the University of Nebraska Medical Center in Omaha, Nebraska. PlasmaTech is also developing AAV gene therapies for the treatment of Sanfilippo syndromes (MPS IIIA and MPS IIIB).
An inherited genetic disorder, juvenile Batten disease is a lysosomal storage disease that primarily affects the nervous system in children. After a few years of normal development, children with this condition experience progressive vision loss leading to blindness, intellectual and motor disability, speech difficulties, seizures, and premature death. As yet, there are no treatments accessible that can halt or reverse the symptoms of Batten disease.
PlasmaTech Biopharmaceuticals, Inc. operates as a biopharmaceutical company and develops protein biologic therapies and oncology supportive care products. The companys marketed product comprises MuGard the administration of oral mucositis; and ProctiGard for the treatment of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
